Table 2:

Heterogeneity of frontline therapy for pediatric MPAL

Induction Therapy	Post-induction Therapy, n (%)†
	ALL only	ALL +HSCT	AML only	AML +HSCT	Hybrid only	Hybrid +HSCT	HSCT only	Missing§§	Total
ALL	21 (38.9)	4 (7.4)	0 (0.0)	2 (3.7)	4 (7.4)	0 (0.0)	3 (5.6)	5 (9.3)	39 (72.2)
AML	2 (3.7)	0 (0.0)	4 (7.4)	3 (5.6)	0 (0.0)	0 (0.0)	2 (3.7)	2 (3.7)	13 (24.1)
Hybrid‡	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (3.7)	0 (0.0)	0 (0.0)	2 (3.7)
Total	23 (42.6)	4 (7.4)	4 (7.4)	5 (9.3)	4 (7.4)	2 (3.7)	5 (9.3)	7 (13.0)	54 (100)

^†percent of total cohort.

^‡Hybrid= components of AML + ALL therapy (n=2).

Regimen #1= prednisone, thioguanine, cytarabine, daunorubicin, vincristine, asparaginase); Regimen #2= cytarabine, daunorubicin, etoposide, prednisone, vincristine, asparaginase, ifosfamide, etoposide);

^§Missing= no data available.